Clinical trials: asthma
COPD Asthma
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
- Trial name
- REDEFINE (NCT03137303)
- Testing
- Spirometry at initial visit, Albuterol, Spirometry at 12-month follow-up
- Where
- 2 sites in United States
- Volunteers
- 402 people
- Sponsor
- University of Illinois Chicago
Asthma
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma
The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.
- Trial name
- NCT01555151
- Testing
- Mometasone furoate, Concept 1, Twisthaler
- Where
- 165 sites in Belgium, Canada and 15 more
- Volunteers
- 739 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily regimen from a new dry powder inhaler (nDPI)…
- Trial name
- NCT01720069
- Testing
- VR506
- Where
- 77 sites in United States, Bulgaria and 6 more
- Volunteers
- 197 people
- Sponsor
- Vectura Limited
Asthma
Local Phase 4 Pan-European SMART Study
The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period
- Trial name
- NCT00463866
- Testing
- Budesonide/formoterol
- Where
- 817 sites in Belgium, Finland and 12 more
- Volunteers
- 8,424 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
Asthma
Study of the Mechanisms of Asthma
The purpose of this study is to identify the causes of asthma that were not previously suspected, to better understand the effects of inhaled steroids on asthma and to identify new way to treat asthma.
- Trial name
- MAST (NCT00595153)
- Testing
- Pulmicort
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Asthma
Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers
The purpose of this study is to investigate exacerbations in severe asthma with regard to symptoms, lung function, aetiology and biomarkers.
- Trial name
- NCT02660853
- Testing
- FEV1
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Imperial College London
COPD, Cystic Fibrosis
Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders
The purpose of this study is to test the efficacy of Hyperpolarized Helium-3 gas in MR imaging in COPD, asthmatics, CF and healthy volunteers.
- Conditions
- COPD, Cystic Fibrosis, Asthma, Healthy
- Trial name
- NCT00846573
- Testing
- Hyperpolarized Helium-3
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Asthma
A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
- Trial name
- NCT01479595
- Testing
- QBX258
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Asthma
Supporting Asthma Management Behaviors in Aging Adults
A 3-arm, patient-randomized trial among Latino and African-American older adults with poorly-controlled asthma will be conducted to compare the effectiveness of clinic-based vs.
- Trial name
- SAMBA (NCT02316223)
- Testing
- Supporting Asthma Management Behaviors in Aging Adults (SAMBA)
- Where
- 3 sites in United States
- Volunteers
- 406 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Asthma, Airway Inflammation
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation…
- Trial name
- NCT00635882
- Testing
- mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Asthma
RISA Extension Study - Long Term Safety
The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter…
- Trial name
- NCT00401986
- Testing
- Bronchial thermoplasty with the Alair System
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Severe Asthma
Adapting Body Reprogramming for Severe Asthma: a Feasibility Study
There are many symptoms associated with severe asthma, not all of them related to the lung. These are referred to as extra-pulmonary symptoms and their relationship with quality of life is complex.
- Trial name
- BoBSA (NCT04980755)
- Testing
- Body Reprogramming
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Asthma and Rhinitis
Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958.
- Trial name
- NCT02446613
- Testing
- Pollen allergen extract
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests.
- Trial name
- NCT00296491
- Testing
- fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP)
- Where
- 121 sites in United States, Canada and 2 more
- Volunteers
- 725 people
- Sponsor
- GlaxoSmithKline
Asthma
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
For the prophylactic treatment of asthma, FP inhaled aerosol (Flixotide ®) administered via a pressurized metered-dose inhaler (pMDI) was approved in China in adults, adolescents older than 16 years of age and children aged 4 to…
- Trial name
- NCT03273946
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.